THU0104 Both MRI and HAQ-DI can predict relapses following all treatment withdrawal in MTX-NAÏVE patients with RA in remission after 12 months of abatacept therapy in the avert trial

H Ahmad; J Baker; M Østergaard; P Emery; T Huizinga; J Ye; S Banerjee; P Conaghan

doi:10.1136/annrheumdis-2017-eular.1649

THU0104 Both MRI and HAQ-DI can predict relapses following all treatment withdrawal in MTX-NAÏVE patients with RA in remission after 12 months of abatacept therapy in the avert trial

H Ahmad, J Baker, M Østergaard, P Emery, T Huizinga, J Ye, S Banerjee, P Conaghan

Department of Clinical Medicine

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	76
Issue number	suppl 2
Pages (from-to)	240
ISSN	0003-4967
DOIs	https://doi.org/10.1136/annrheumdis-2017-eular.1649
Publication status	Published - 2017

Access to Document

10.1136/annrheumdis-2017-eular.1649

240.1.full.pdfFinal published version, 131 KB

Cite this

Ahmad, H., Baker, J., Østergaard, M., Emery, P., Huizinga, T., Ye, J., Banerjee, S., & Conaghan, P. (2017). THU0104 Both MRI and HAQ-DI can predict relapses following all treatment withdrawal in MTX-NAÏVE patients with RA in remission after 12 months of abatacept therapy in the avert trial. Annals of the Rheumatic Diseases, 76(suppl 2), 240. https://doi.org/10.1136/annrheumdis-2017-eular.1649

THU0104 Both MRI and HAQ-DI can predict relapses following all treatment withdrawal in MTX-NAÏVE patients with RA in remission after 12 months of abatacept therapy in the avert trial. / Ahmad, H; Baker, J; Østergaard, M et al.

In: Annals of the Rheumatic Diseases, Vol. 76, No. suppl 2, 2017, p. 240.

Research output: Contribution to journal › Conference abstract in journal › Research

Ahmad, H, Baker, J, Østergaard, M, Emery, P, Huizinga, T, Ye, J, Banerjee, S & Conaghan, P 2017, 'THU0104 Both MRI and HAQ-DI can predict relapses following all treatment withdrawal in MTX-NAÏVE patients with RA in remission after 12 months of abatacept therapy in the avert trial', Annals of the Rheumatic Diseases, vol. 76, no. suppl 2, pp. 240. https://doi.org/10.1136/annrheumdis-2017-eular.1649

@article{b6112852c31b4b1fba437330d5d6bf12,

title = "THU0104 Both MRI and HAQ-DI can predict relapses following all treatment withdrawal in MTX-NA{\"I}VE patients with RA in remission after 12 months of abatacept therapy in the avert trial",

author = "H Ahmad and J Baker and M {\O}stergaard and P Emery and T Huizinga and J Ye and S Banerjee and P Conaghan",

year = "2017",

doi = "10.1136/annrheumdis-2017-eular.1649",

language = "English",

volume = "76",

pages = "240",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "suppl 2",

}

TY - ABST

T1 - THU0104 Both MRI and HAQ-DI can predict relapses following all treatment withdrawal in MTX-NAÏVE patients with RA in remission after 12 months of abatacept therapy in the avert trial

AU - Ahmad, H

AU - Baker, J

AU - Østergaard, M

AU - Emery, P

AU - Huizinga, T

AU - Ye, J

AU - Banerjee, S

AU - Conaghan, P

PY - 2017

Y1 - 2017

U2 - 10.1136/annrheumdis-2017-eular.1649

DO - 10.1136/annrheumdis-2017-eular.1649

M3 - Conference abstract in journal

SN - 0003-4967

VL - 76

SP - 240

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - suppl 2

ER -